Related Experiment Video
Updated: Jun 18, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma
Feras E Machour1, Enas R Abu-Zhayia1, Joyce Kamar2
1Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Abstract:
The splicing factor RNA-binding motif protein 10 (RBM10) is frequently mutated in lung adenocarcinoma (LUAD) (9-25%). Most RBM10 cancer mutations are loss-of-function, correlating with increased tumorigenesis and limiting the efficacy of current LUAD targeted therapies. Remarkably, therapeutic strategies leveraging RBM10 deficiency remain unexplored. Here, we conduct a CRISPR-Cas9 synthetic lethality (SL) screen and identify ~60 RBM10 SL genes, including WEE1 kinase. WEE1 inhibition sensitizes RBM10-deficient LUAD cells in-vitro and in-vivo. Mechanistically, we identify a splicing-independent role of RBM10 in regulating DNA replication fork progression and replication stress response, which underpins RBM10-WEE1 SL. Additionally, RBM10 interacts with active DNA replication forks, relying on DNA Primase Subunit 1 (PRIM1) that synthesizes Okazaki RNA primers. Functionally, we demonstrate that RBM10 serves as an anchor for recruiting Histone Deacetylase 1 (HDAC1) to facilitate H4K16 deacetylation and R-loop homeostasis to maintain replication fork stability. Collectively, our data reveal a role of RBM10 in fine-tuning DNA replication and provide therapeutic arsenal for targeting RBM10-deficient tumors.
Insights
Targeting RNA-binding motif protein 10 (RBM10) deficiency in lung adenocarcinoma (LUAD) is a novel therapeutic strategy. Inhibiting WEE1 kinase exploits RBM10 loss-of-function, offering new treatment options for LUAD patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RNA-binding motif protein 10 (RBM10) is frequently mutated in lung adenocarcinoma (LUAD), with loss-of-function mutations correlating with increased tumorigenesis.
- Current LUAD targeted therapies are limited by RBM10 mutations, and therapeutic strategies exploiting RBM10 deficiency remain unexplored.
Purpose of the Study:
- To identify therapeutic targets synthetic lethal with RBM10 deficiency in LUAD.
- To elucidate the functional role of RBM10 in DNA replication and replication stress response.
Main Methods:
- CRISPR-Cas9 synthetic lethality (SL) screen to identify RBM10 SL genes.
- In vitro and in vivo studies to assess the efficacy of WEE1 inhibition in RBM10-deficient LUAD cells.
- Mechanistic studies involving DNA replication fork progression, replication stress response, and protein-protein interactions.
Main Results:
- Identified approximately 60 RBM10 SL genes, including WEE1 kinase.
- WEE1 inhibition demonstrated efficacy in sensitizing RBM10-deficient LUAD cells both in vitro and in vivo.
- Uncovered a splicing-independent role of RBM10 in regulating DNA replication fork stability through interaction with PRIM1 and recruitment of HDAC1 for H4K16 deacetylation and R-loop homeostasis.
Conclusions:
- RBM10 plays a critical role in maintaining DNA replication fork stability and replication stress response.
- WEE1 inhibition represents a promising therapeutic strategy for RBM10-deficient LUAD.
- This study provides a new therapeutic avenue for targeting LUAD tumors with RBM10 mutations.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation
The Ras Gene
Ras is a...

